Plunkett Research Online: Akebia Therapeutics Inc

AKEBIA THERAPEUTICS INC (AKBA:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States.....



Akebia Therapeutics Inc
Ticker: AKBA
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617 871-2098
Fax:
Address: 245 First Street
Suite 1400
Cambridge, MA 02142 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Biopharmaceutical Development
Biopharmaceutical Production
Contacts Description
John ButlerCEO/Director/President
Erik OstrowskiCFO/Other Executive Officer/Senior VP/Treasurer
See More
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202520242023202220212020
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Auryxia
Vadadustat
Riona
Fexeric
NameTitleSalary (US$)Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: